Northwestern Mutual Wealth Management Co. Decreases Position in Anavex Life Sciences Corp. $AVXL

Northwestern Mutual Wealth Management Co. cut its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 46.1% in the 1st quarter, Holdings Channel reports. The institutional investor owned 14,871 shares of the biotechnology company’s stock after selling 12,698 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Anavex Life Sciences were worth $128,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Anavex Life Sciences by 4.7% in the first quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company’s stock worth $42,061,000 after buying an additional 221,802 shares during the last quarter. Nwam LLC raised its holdings in shares of Anavex Life Sciences by 9.6% during the first quarter. Nwam LLC now owns 1,000,351 shares of the biotechnology company’s stock valued at $8,583,000 after purchasing an additional 87,300 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Anavex Life Sciences by 1.6% during the fourth quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company’s stock valued at $7,592,000 after purchasing an additional 10,938 shares during the last quarter. LPL Financial LLC raised its holdings in shares of Anavex Life Sciences by 482.1% during the first quarter. LPL Financial LLC now owns 546,626 shares of the biotechnology company’s stock valued at $4,690,000 after purchasing an additional 452,723 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its holdings in shares of Anavex Life Sciences by 197.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 248,139 shares of the biotechnology company’s stock valued at $2,129,000 after purchasing an additional 164,792 shares during the last quarter. 31.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVXL has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a report on Friday, August 22nd. Wall Street Zen cut shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 23rd. Finally, D. Boral Capital reissued a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday, August 27th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $44.00.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $9.40 on Friday. The company’s fifty day simple moving average is $10.54 and its 200-day simple moving average is $9.28. The stock has a market capitalization of $807.37 million, a PE ratio of -16.49 and a beta of 0.83. Anavex Life Sciences Corp. has a 1-year low of $4.93 and a 1-year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, research analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.